NGL Fine-Chem Ltd. (NGLFINE): NGL Fine-Chem Share Price Falls 8.02%: Small Cap Stock Analysis

NGL Fine-Chem Share Price fell to Rs 3,185, down 8.02% today. The small cap pharmaceutical stock has a market capitalisation of Rs 2,139.2 crore.

NGL Fine-Chem Share Price is in focus on 17 August 2026 after the stock fell 8.02% to Rs 3,185 from the previous close of Rs 3,462.6, taking the company’s market capitalisation to Rs 2,139.2 crore. The move places NGL Fine-Chem Ltd. among the top decliners being tracked in the small cap space, and it is notable because the verified data confirms that the stock cleared the qualifying bar for its market-cap category.

For investors searching NGL Fine-Chem Share Price Today, the immediate picture is clear: the stock opened at Rs 3,515.85, touched the same level as the day’s high, and then slid to an intraday low of Rs 3,111.9 before trading at Rs 3,185 at the time captured in this Univest update. The supplied data establishes the price event, but it does not establish a company-specific catalyst behind the decline.

That still leaves several useful signals to examine. Price action shows a decisive gap down from the previous close and sustained weakness through the session. Fundamental analysis shows a stock trading at a P/E ratio of 37.4 and a P/B ratio of 6.15, while profitability remains strong with ROE of 27.9% and ROCE of 33.91%. Investors tracking NGL Fine-Chem Stock News should now watch how price behaviour, valuation context and peer positioning interact rather than drawing conclusions from the single-day move alone. Univest therefore looks at today’s decline through price, sector and financial quality lenses.

NGL Fine-Chem Ltd. (NGLFINE) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 3,185
Previous Close	Rs 3,462.6
Today's Change	Rs -277.6 (-8.02%)
Day Open	Rs 3,515.85
Day High	Rs 3,515.85
Day Low	Rs 3,111.9
Current Volume (BSE)	1,209
BSE Traded Volume	1,209
NSE Traded Volume	23,470
Combined NSE + BSE Volume	24,679
Turnover	Rs 0.39 crore
Market Capitalisation	Rs 2,139.2 crore
Market Cap Category	Small Cap

NGL Fine-Chem Ltd. (NGLFINE) traded at Rs 3,185. versus the previous close of Rs 3,462.6, a fall of 8.02%. The stock opened at Rs 3,515.85, reached Rs 3,515.85, touched Rs 3,111.9. Reported volume was 1,209.

NGL Fine-Chem Ltd. (NGLFINE) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 2,139.2 crore
P/E Ratio	37.4x
P/B Ratio	6.15x
ROE	27.9%
ROCE	33.91%
EPS	Rs 92.59
Dividend Yield	0.05%

NGL Fine-Chem Ltd. was valued at a P/E ratio of 37.4x, a P/B ratio of 6.15x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 27.9% and ROCE of 33.91%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 92.59, dividend yield of 0.05%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

NGL Fine-Chem Fundamental Analysis shows a mix that can keep investors interested even after a sharp down day: a relatively elevated valuation against some benchmarks, but also strong return ratios. With a market capitalisation of Rs 2,139.2 crore, NGL Fine-Chem Ltd. sits firmly in the small cap bucket, which speaks to company size rather than business quality.

Profitability, however, is notably strong. ROE is 27.9%, showing healthy returns generated on shareholder equity, while ROCE is 33.91%, indicating robust returns on capital employed. These are the sort of ratios that often attract attention in NGL Fine-Chem Stock Analysis because they imply that the company has so far been able to convert its capital base into comparatively strong returns.

Dividend yield is 0.05. That is a historical or current yield indicator based on the supplied data, not a forward payout promise, but it does show that income contribution is minimal compared with the stock price level. In practical terms, investors looking at NGL Fine-Chem Share News are unlikely to view the stock primarily as a dividend play.

Taken together, the supplied fundamentals do add context to investor interest. The company is not being priced like a distressed business: its P/E and P/B remain substantial, and its ROE, ROCE and EPS provide evidence of earnings power and capital efficiency. That combination means today’s price fall matters because it is happening in a stock that still screens as fundamentally profitable on the supplied ratios. The next step is to place those figures beside sector benchmarks to see whether the valuation and returns stand out within pharmaceuticals and drugs.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	37.4x
Benchmark Median P/E	26.47x
Benchmark Average P/E	40.28x
Benchmark P/E Range	2.98x to 361.02x
Company P/B Ratio	6.15x
Benchmark Median P/B	1.77x
Company ROE	27.9%
Benchmark Median ROE	9.91%
Company ROCE	33.91%
Benchmark Median ROCE	12.79%
Company Market Capitalisation	Rs 2,139.2 crore
Benchmark Median Market Cap	Rs 137.8 crore

NGL Fine-Chem Ltd. (NGLFINE) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

NGL Fine-Chem Ltd. (NGLFINE) has a P/E ratio of 37.4x, which is above the benchmark median of 26.47x, a difference of +41.29%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

NGL Fine-Chem Ltd. (NGLFINE) has a ROE of 27.9%, which is above the benchmark median of 9.91%, a difference of +181.53%. NGL Fine-Chem Ltd. (NGLFINE) has a ROCE of 33.91%, which is above the benchmark median of 12.79%, a difference of +165.13%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

NGL Fine-Chem operates in Healthcare, specifically the Pharmaceuticals & Drugs industry, and the sector benchmark supplied here covers the same industry across 139 companies. That makes the comparison useful because it places the company against a large listed peer set rather than a broad market average.

The biggest valuation contrast is in P/E. NGL Fine-Chem’s P/E ratio is 37.4. Within the same-industry benchmark, the median P/E is 26.47, the average is 40.28, the minimum is 2.98 and the maximum is 361.02, based on 105 companies with available P/E data. This means the stock is trading above the industry median but below the industry average. In other words, NGL Fine-Chem Share Price is not cheap relative to the middle of the sector pack, though it is also far from the most richly valued name in the benchmark range.

P/B tells a firmer story. The company’s P/B of 6.15 is well above the industry median of 1.77 and the average of 2.33 across 138 companies. That suggests the market values its equity base at a notable premium to much of the industry. Investors reviewing NGL Fine-Chem Fundamental Analysis should connect that premium with profitability.

On returns, the company stands out positively. ROE of 27.9% is far higher than the benchmark median of 9.91% and the average of 7.3. ROCE of 33.91% is also comfortably above the median of 12.79% and the average of 14.83. Market-cap positioning is also notable: NGL Fine-Chem’s Rs 2,139.2 crore market capitalisation is much higher than the industry median of Rs 137.8 crore and well above the average of Rs 481.52 crore, though still below the benchmark maximum of Rs 2,985.15 crore.

The broad conclusion from this Univest sector view is balanced. NGL Fine-Chem carries a premium balance-sheet multiple, but that premium sits alongside superior profitability metrics within its Pharmaceuticals & Drugs peer universe.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,985.15	184.72	0.45	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,827.67	68.16	6.74	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.26	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,645.37	46.15	1.77	-0.78	8.31
Fredun Pharmaceuticals Ltd.	FREDUN	2,559.68	58.41	8.73	11.42	13.15

NGL Fine-Chem Ltd. (NGLFINE) has a P/E ratio of 37.4x compared with the displayed peer median of 58.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 27.9% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 33.91% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. NGL Fine-Chem Ltd. (NGLFINE) has a market capitalisation of Rs 2,139.2 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

NGL Fine-Chem’s peer set places it among mid-sized listed pharmaceutical names where valuation and profitability can diverge sharply. Comparing the supplied numbers shows that the company sits below the market capitalisation of several named peers, but its return ratios are stronger than many of them.

At Rs 2,139.2 crore, NGL Fine-Chem’s market cap is below Dishman Carbogen Amcis at Rs 2,985.15 crore, Beta Drugs at Rs 2,827.67 crore, Hikal at Rs 2,686.72 crore, Ind-Swift Laboratories at Rs 2,645.37 crore and Fredun Pharmaceuticals at Rs 2,559.68 crore. It is also below Solara Active Pharma Sciences at Rs 2,465.73 crore, Sai Parenteral’s at Rs 2,438.25 crore, Panacea Biotec at Rs 2,429.2 crore and Venus Remedies at Rs 2,388.41 crore. So on size, NGL Fine-Chem is smaller than the supplied peer group.

On valuation, its P/E of 37.4 is lower than Dishman Carbogen Amcis at 184.72, Beta Drugs at 68.16, Ind-Swift Laboratories at 46.15, Fredun Pharmaceuticals at 58.41 and Sai Parenteral’s at 171, but higher than Venus Remedies at 20.56. That places NGL Fine-Chem in a middle zone rather than at an extreme.

The profitability comparison is more favourable. ROE of 27.9% is above Beta Drugs at 18.65, Hikal at 15.22, Fredun Pharmaceuticals at 11.42, Sai Parenteral’s at 13.9 and Venus Remedies at 9.85. It is also above Dishman Carbogen Amcis at -2.89 and Ind-Swift Laboratories at -0.78. ROCE of 33.91% similarly exceeds the supplied peer figures, including Beta Drugs at 22.17 and Hikal at 16.15. This is why NGL Fine-Chem Stock News remains worth monitoring despite today’s fall: the market may be reacting within a stock that still compares well on operational returns.

Why Investors Are Watching NGL Fine-Chem

NGL Fine-Chem is being watched because today’s decline is large enough to stand out in Share Market Today screens, yet the company’s profitability profile remains stronger than many industry peers. For investors tracking NGL Fine-Chem Share Price Update and Stocks in News, the stock now sits at an important intersection of price weakness and comparatively solid return ratios.

• Price action: The stock fell 8.02% to Rs 3,185 from Rs 3,462.6, with the opening price of Rs 3,515.85 also marking the day’s high.
• Intraday pressure: The stock touched a low of Rs 3,111.9, showing that selling pressure persisted through the session.
• Participation: Total traded volume was 24,679 shares and turnover stood at Rs 0.39 crore.
• Fundamentals: P/E is 37.4, P/B is 6.15, ROE is 27.9%, ROCE is 33.91%, EPS is 92.59 and dividend yield is 0.05.
• Sector position: Profitability metrics are above industry medians and averages, while valuation sits above the P/E median and well above the P/B median.

What should investors monitor next? Univest would focus on whether NGL Fine-Chem Share Price stabilises after today’s fall, how the stock trades relative to its recent valuation premium, and whether future company updates justify return ratios that currently outpace many peers in Pharmaceuticals & Drugs. That is a monitoring framework, not a recommendation.

About NGL Fine-Chem

NGL Fine-Chem Ltd. is a listed company in the Healthcare sector and Pharmaceuticals & Drugs industry. That industry context matters because it places the company in a segment where investors often compare valuation against profitability, scale and return ratios rather than price action alone.

Based on the supplied company context, NGL Fine-Chem should be viewed primarily through its positioning inside the pharmaceutical ecosystem. Its market capitalisation of Rs 2,139.2 crore is significantly above the same-industry median market cap of Rs 137.8 crore and also above the average of Rs 481.52 crore across 139 benchmark companies. That suggests it is meaningfully larger than a typical listed company in this industry sample, even though it remains a small cap stock by category.

The company’s financial profile also distinguishes it within that listed universe. A P/E of 37.4 and P/B of 6.15 indicate that the market has been willing to assign a premium multiple, while ROE of 27.9% and ROCE of 33.91% show strong capital efficiency relative to industry norms. For readers following NGL Fine-Chem Latest News and NGL Fine-Chem Company News, this combination explains why the stock can attract attention even on a weak day: the business metrics and the market’s pricing of those metrics remain central to the investment debate.

Track NGL Fine-Chem Share Price on Univest

Use NGL Fine-Chem Ltd. (NGLFINE) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Users tracking NGL Fine-Chem Share Price on Univest can follow live share price moves, daily stock performance, valuation ratios, profitability indicators and sector context in one place. That includes price action such as open, high, low, previous close and day change, alongside metrics like P/E, P/B, ROE, ROCE, EPS, dividend yield and market capitalisation.

Univest also helps readers monitor how NGL Fine-Chem Share Price Today compares with peers in Healthcare and Pharmaceuticals & Drugs, while keeping an eye on broader market movers, 52 week levels and stock analysis signals available on the platform. For investors who prefer verified numbers over speculation, that makes Univest a practical way to track NGL Fine-Chem Stock News as it develops.

Frequently Asked Questions

Why is NGL Fine-Chem Share Price falling today?

Ans. NGL Fine-Chem Share Price fell 8.02% to Rs 3,185 from the previous close of Rs 3,462.6. The supplied data confirms the price fall event, but it does not establish a company-specific catalyst behind today’s decline.

What was the opening, high and low for NGL Fine-Chem today?

Ans. The stock opened at Rs 3,515.85, and that was also the day’s high. It later fell to an intraday low of Rs 3,111.9 before trading at Rs 3,185 in the captured market update.

How much market capitalisation does NGL Fine-Chem have?

Ans. NGL Fine-Chem had a market capitalisation of Rs 2,139.2 crore in the supplied data. That places it in the Small Cap category and above the Pharmaceuticals & Drugs industry median market cap of Rs 137.8 crore.

Is NGL Fine-Chem expensive on P/E compared with its industry?

Ans. The company’s P/E ratio is 37.4. That is above the same-industry median of 26.47 but below the average of 40.28 across 105 companies with available P/E data, so valuation is elevated versus the median, not the average.

How does NGL Fine-Chem compare on P/B ratio?

Ans. NGL Fine-Chem trades at a P/B ratio of 6.15. In the supplied Pharmaceuticals & Drugs benchmark, the median P/B is 1.77 and the average is 2.33, showing the stock carries a premium to industry balance-sheet multiples.

Are NGL Fine-Chem’s profitability ratios strong?

Ans. ROE stands at 27.9% and ROCE at 33.91%, which are both well above the industry median figures of 9.91% and 12.79. Those numbers suggest stronger capital efficiency than much of the listed peer universe.

What does EPS and dividend yield show for NGL Fine-Chem?

Ans. EPS is 92.59, indicating the earnings attributable to each share on the supplied data. Dividend yield is 0.05, which shows only a modest historical or current yield contribution relative to the prevailing stock price.

How active was trading in NGL Fine-Chem shares today?

Ans. Total traded volume was 24,679 shares, made up of 1,209 shares on BSE and 23,470 shares on NSE. The supplied turnover was Rs 0.39 crore, giving a basic measure of cash participation in today’s decline.

How does NGL Fine-Chem compare with peers on returns?

Ans. NGL Fine-Chem’s ROE of 27.9% is above peers such as Beta Drugs at 18.65 and Hikal at 15.22. Its ROCE of 33.91% also exceeds the supplied peer figures, making returns a relative strength.

What should investors monitor after today’s fall?

Ans. Investors can monitor whether the stock stabilises after falling to Rs 3,185, how valuation metrics such as P/E 37.4 and P/B 6.15 are viewed, and whether future updates continue supporting strong ROE and ROCE.